The purpose of this study is to evaluate the efficacy of terlipressin for treating septic shock.
Septic shock is the most common cause of death in intensive care units and has a mortality rate of 40 to 60%.Vasopressin is commonly used as an adjunct to catecholamines to support blood pressure in refractory septic shock.Recently small sample clinical study suggest that Terlipressin,a vasopressin analogues, was effective in reversing sepsis-induced arterial hypotension and in reducing norepinephrine requirements.But its effect on mortality is unknown.Invesgators hypothesized that Terlipressin as compared with norepinephrine would decrease mortality among patients with septic shock.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
1,000
continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
Surgical intensive care unit, 1st affiliated hospital of Sun Yat-sen university
Guangzhou, Guangdong, China
RECRUITING28-day Mortality
The prospectively defined primary end point was death from any cause and was assessed 28 days after the start of the infusion
Time frame: 28-days
SOFA score
SOFA score was measured on day0-7 after the start of the infusion in both groups
Time frame: 7 days
days alive and free of vasopressor
Days of vasopressor were recorded after the start of the infusion in both groups.
Time frame: during the first 28 days after the start of the infusion
90-day mortality
Time frame: 90 days after the start of the infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.